-
Mashup Score: 16ENZA-p Trial Shows Promise for Enzalutamide-Lutetium Combination in Prostate Cancer - Louise Emmett - 2 day(s) ago
Alicia Morgans speaks with Louise Emmett about the ENZA-p study, presented at ESMO 2023. This groundbreaking research explores the combination of lutetium and enzalutamide in treating early metastatic castrate-resistant prostate cancer. Patients, previously showing limited response to enzalutamide, were screened with PSMA PET and randomized to receive either enzalutamide alone or combined with…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 0
Andrea Miyahira hosts Ping Mu to discuss his group’s research on prostate cancer resistance to anti-androgens. Dr. Mu’s study, published in Oncogene, focuses on the gene UBE2J1, identified as a key E2 ubiquitin-conjugating enzyme regulating Androgen Receptor (AR) degradation. He explains that despite advancements in anti-androgen therapies like enzalutamide, resistance remains a significant…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 2Identification of genes that promote PI3K pathway activation and prostate tumour formation - 2 day(s) ago
Oncogene – Identification of genes that promote PI3K pathway activation and prostate tumour formation
Source: www.nature.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 18
prostate cancer, PARP Inhibitor Therapy, Poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitors, PARP inhibitors, androgen receptor pathway inhibitor (ARPI), homologous recombination repair (HRR) genes, Olaparib plus Radium-223, Olaparib, Radium-223, Niraparib, abiraterone, enzalutamide, Talazoparib, Niraparib plus abiraterone, Talazoparib plus enzalutamide, COMRADE trial, BRCA1/2 alterations, KEYNOTE-365 study, Pembrolizumab, Durvalumab, avelumab, Bipolar Androgen Therapy (BAT), supraphysiologic testosterone (SPT), Cediranib, Olaparib plus Cediranib, Rad3-related protein (ATR) inhibitor, ceralasterib, TRAP trial, KEYLYNK-010 Trial, JAVELIN PARP Medley trial,
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 0
Patient/provider trust, education and lifestyle choices are crucial as Black men face higher incidence and mortality in prostate cancer, experts said.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet
-
Mashup Score: 0Targeting the Androgen Receptor Pathway and Overcoming Treatment Resistance in Advanced Prostate Cancer - 3 day(s) ago
This segment delves into targeting the androgen receptor pathway and conquering treatment resistance for potential breakthroughs in managing advanced prostate cancer.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Unlocking Precision Care: Germline & Somatic Literacy in Prostate Cancer - Elisabeth Heath - 3 day(s) ago
Program: Beyond Androgen Blockade – New Pathways and Novel Treatments in mHSPC and mCRPC Unlocking Precision Care: Germline & Somatic Literacy in Prostate Cancer – Elisabeth Heath Part of an Independent Medical Education Initiative Supported by LOXO@Lilly> Biographies: Elisabeth I. Heath, MD, FACP, Associate Center Director of Translational Sciences, Hartmann Endowed Chair for Prostate Cancer…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 2
Dan George discusses the collaborative effort in managing PLUVICTO® therapy for prostate cancer with team members Kristen Davis and Sarah Wood. Dr. Davis describes the meticulous process of vetting patients for PLUVICTO® therapy, which includes reviewing patient information, scans, and coordinating with various departments for approval. Dr. Wood outlines her role in educating and managing…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Operationalizing and coordinating lutetium-177 PSMA treatment: roles of a multidisciplinary #ProstateCancer team. Kristen Davis, Sarah Yenser Wood, and @Daniel_J_George @DukeCancer underline the importance of a team approach and effective communication > https://t.co/sC6IxJAzNn https://t.co/Rzxf0yPPMl
-
-
Mashup Score: 0The Complex Interplay of Factors Driving Prostate Cancer Disparities - Steven Patierno - 3 day(s) ago
Steven Patierno delves into his 25-year journey tackling cancer disparities, with a focus on prostate cancer. Beginning in Washington D.C., Dr. Patierno’s work highlighted the stark impact of socioeconomic factors and healthcare access on cancer care. At Duke, he leads a comprehensive approach addressing the intricate mix of social inequities, healthcare access, and ancestry-related biology. He…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 17How to Report PSMA PET - Beyond the Abstract - 4 day(s) ago
methods to convey PSMA-PET/CT results, prostate cancer, Prostate-Specific Membrane Antigen (PSMA), PSMA PET, 177Lu-PSMA-SPECT, biochemical recurrence (BCR), PROMISE, PRIMARY, PSMA_RADS, E-PSMA.
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
ENZA-p trial shows promise for enzalutamide-lutetium combination in #ProstateCancer. @drlouiseemmett @UNSW joins @CaPsurvivorship @DanaFarber to discuss this groundbreaking research in a conversation on UroToday > https://t.co/E0e6mswCEk https://t.co/g0clwCmEXF